Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRES extension study of oral imatinib for severe pulmonary arterial hypertension
NL-OMON34535Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoint: Adverse events. Started Dec 2010; status: active, not recruiting.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON34535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34535.